NZ596753A - Phenoxymethyl heterocyclic compounds - Google Patents
Phenoxymethyl heterocyclic compoundsInfo
- Publication number
- NZ596753A NZ596753A NZ596753A NZ59675309A NZ596753A NZ 596753 A NZ596753 A NZ 596753A NZ 596753 A NZ596753 A NZ 596753A NZ 59675309 A NZ59675309 A NZ 59675309A NZ 596753 A NZ596753 A NZ 596753A
- Authority
- NZ
- New Zealand
- Prior art keywords
- disorder
- pyridin
- phenyl
- compounds
- ylmethoxy
- Prior art date
Links
- -1 Phenoxymethyl heterocyclic compounds Chemical class 0.000 title abstract 2
- 208000028017 Psychotic disease Diseases 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000022821 personality disease Diseases 0.000 abstract 2
- VZEFBYIBQRLFAX-UHFFFAOYSA-N 4-[3-[4-(imidazo[1,2-a]pyridin-2-ylmethoxy)phenyl]-5,5-dimethyl-4-oxofuran-2-yl]benzonitrile Chemical compound C=1C=C(OCC=2N=C3C=CC=CN3C=2)C=CC=1C=1C(=O)C(C)(C)OC=1C1=CC=C(C#N)C=C1 VZEFBYIBQRLFAX-UHFFFAOYSA-N 0.000 abstract 1
- GPFTVIIACHNMNI-UHFFFAOYSA-N 4-[4-(imidazo[1,2-a]pyridin-2-ylmethoxy)phenyl]-5-(4-methoxyphenyl)-2,2-dimethylfuran-3-one Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC(OCC=3N=C4C=CC=CN4C=3)=CC=2)C(=O)C(C)(C)O1 GPFTVIIACHNMNI-UHFFFAOYSA-N 0.000 abstract 1
- AQQONKYJYUDLRR-UHFFFAOYSA-N 5-(4-methoxyphenyl)-2,2-dimethyl-4-[4-[(5-methylimidazo[1,2-a]pyridin-2-yl)methoxy]phenyl]furan-3-one Chemical compound C1=CC(OC)=CC=C1C1=C(C=2C=CC(OCC=3N=C4C=CC=C(C)N4C=3)=CC=2)C(=O)C(C)(C)O1 AQQONKYJYUDLRR-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 206010008748 Chorea Diseases 0.000 abstract 1
- 208000024254 Delusional disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000012661 Dyskinesia Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 abstract 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 abstract 1
- 208000011963 Substance-induced psychotic disease Diseases 0.000 abstract 1
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 abstract 1
- 230000007000 age related cognitive decline Effects 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000002545 drug psychosis Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 208000002851 paranoid schizophrenia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17641309P | 2009-05-07 | 2009-05-07 | |
| PCT/US2009/068644 WO2010128995A1 (en) | 2009-05-07 | 2009-12-18 | Phenoxymethyl heterocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ596753A true NZ596753A (en) | 2013-09-27 |
Family
ID=41549054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ596753A NZ596753A (en) | 2009-05-07 | 2009-12-18 | Phenoxymethyl heterocyclic compounds |
Country Status (32)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009158393A1 (en) | 2008-06-25 | 2009-12-30 | Envivo Pharmaceuticals, Inc. | 1, 2 disubstituted heterocyclic compounds |
| NZ596753A (en) | 2009-05-07 | 2013-09-27 | Envivo Pharmaceuticals Inc | Phenoxymethyl heterocyclic compounds |
| US8772316B2 (en) | 2011-02-18 | 2014-07-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A) |
| JP6215315B2 (ja) | 2012-06-12 | 2017-10-18 | アッヴィ・インコーポレイテッド | ピリジノンおよびピリダジノン誘導体 |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| ES2480341B1 (es) | 2013-01-24 | 2015-01-22 | Palobiofarma S.L | Nuevos derivados de pirimidina como inhibidores de la fosfodiesterasa 10 (PDE-10) |
| TW201512201A (zh) * | 2013-03-14 | 2015-04-01 | Forum Pharmaceuticals Inc | 化合物的多晶型及鹽類 |
| TWI634114B (zh) * | 2013-05-08 | 2018-09-01 | 永恒生物科技公司 | 作為激酶抑制劑之呋喃酮化合物 |
| US10039764B2 (en) | 2013-07-12 | 2018-08-07 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE318809T1 (de) * | 1999-11-05 | 2006-03-15 | Sod Conseils Rech Applic | Heterocyclische verbindungen und ihre verwendung als medikamente |
| US20030032579A1 (en) | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| JPWO2004002484A1 (ja) | 2002-06-26 | 2005-10-27 | 協和醗酵工業株式会社 | ホスホジエステラーゼ阻害剤 |
| WO2006072828A2 (en) | 2005-01-07 | 2006-07-13 | Pfizer Products Inc. | Heteroaromatic quinoline compounds and their use as pde10 inhibitors |
| NL2000397C2 (nl) * | 2006-01-05 | 2007-10-30 | Pfizer Prod Inc | Bicyclische heteroarylverbindingen als PDE10 inhibitoren. |
| EP1845098A1 (en) * | 2006-03-29 | 2007-10-17 | Ferrer Internacional, S.A. | Imidazo[1,2-b]pyridazines, their processes of preparation and their use as GABA receptor ligands |
| JP2009535394A (ja) | 2006-05-02 | 2009-10-01 | ファイザー・プロダクツ・インク | Ｐｄｅ１０阻害剤としての二環式ヘテロアリール化合物 |
| WO2008033455A2 (en) | 2006-09-13 | 2008-03-20 | The Institutes For Pharmaceutical Discovery, Llc | Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors |
| FR2928924B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique |
| WO2009158393A1 (en) | 2008-06-25 | 2009-12-30 | Envivo Pharmaceuticals, Inc. | 1, 2 disubstituted heterocyclic compounds |
| NZ596753A (en) | 2009-05-07 | 2013-09-27 | Envivo Pharmaceuticals Inc | Phenoxymethyl heterocyclic compounds |
| AU2010289353B2 (en) * | 2009-09-03 | 2016-12-08 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| SI3311666T1 (sl) * | 2010-08-18 | 2021-09-30 | Biosplice Therapeutics, Inc. | Diketoni in hidroksiketoni, kot aktivatorji signalne poti katenina |
-
2009
- 2009-12-18 NZ NZ596753A patent/NZ596753A/xx not_active IP Right Cessation
- 2009-12-18 ES ES13150322.9T patent/ES2554788T3/es active Active
- 2009-12-18 ME MEP-2015-210A patent/ME02375B/me unknown
- 2009-12-18 WO PCT/US2009/068644 patent/WO2010128995A1/en active Application Filing
- 2009-12-18 CN CN201510438849.1A patent/CN105125547A/zh active Pending
- 2009-12-18 KR KR1020117028223A patent/KR101662699B1/ko not_active Expired - Fee Related
- 2009-12-18 RS RS20150803A patent/RS54529B1/en unknown
- 2009-12-18 HU HUE13150322A patent/HUE026238T2/en unknown
- 2009-12-18 RS RS20130218A patent/RS52838B/en unknown
- 2009-12-18 DK DK13150322.9T patent/DK2617420T3/da active
- 2009-12-18 AU AU2009345802A patent/AU2009345802B2/en not_active Ceased
- 2009-12-18 CN CN200980159735.6A patent/CN102459242B/zh not_active Expired - Fee Related
- 2009-12-18 PE PE2011001918A patent/PE20120900A1/es not_active Application Discontinuation
- 2009-12-18 JP JP2012509778A patent/JP5628902B2/ja not_active Expired - Fee Related
- 2009-12-18 US US12/642,026 patent/US8343973B2/en not_active Expired - Fee Related
- 2009-12-18 SG SG2011081437A patent/SG175900A1/en unknown
- 2009-12-18 PT PT97962179T patent/PT2427454E/pt unknown
- 2009-12-18 MX MX2011011755A patent/MX2011011755A/es active IP Right Grant
- 2009-12-18 CA CA2761032A patent/CA2761032A1/en not_active Abandoned
- 2009-12-18 SI SI200930609T patent/SI2427454T1/sl unknown
- 2009-12-18 PT PT131503229T patent/PT2617420E/pt unknown
- 2009-12-18 EP EP15184753.0A patent/EP3020716A1/en not_active Withdrawn
- 2009-12-18 DK DK09796217.9T patent/DK2427454T3/da active
- 2009-12-18 MY MYPI2011005358A patent/MY183910A/en unknown
- 2009-12-18 ES ES09796217T patent/ES2409404T3/es active Active
- 2009-12-18 EP EP09796217A patent/EP2427454B1/en active Active
- 2009-12-18 EP EP13150322.9A patent/EP2617420B1/en active Active
- 2009-12-18 BR BRPI0924617A patent/BRPI0924617A8/pt not_active IP Right Cessation
- 2009-12-18 PL PL09796217T patent/PL2427454T3/pl unknown
- 2009-12-18 SI SI200931314T patent/SI2617420T1/sl unknown
- 2009-12-18 HR HRP20130482AT patent/HRP20130482T1/hr unknown
- 2009-12-18 RU RU2011149637/04A patent/RU2531274C2/ru not_active IP Right Cessation
- 2009-12-18 PL PL13150322T patent/PL2617420T3/pl unknown
-
2011
- 2011-11-03 IL IL216149A patent/IL216149A/en not_active IP Right Cessation
- 2011-11-07 CL CL2011002792A patent/CL2011002792A1/es unknown
- 2011-11-11 CO CO11153626A patent/CO6460744A2/es active IP Right Grant
- 2011-11-24 EC EC2011011479A patent/ECSP11011479A/es unknown
- 2011-12-05 CR CR20110648A patent/CR20110648A/es unknown
- 2011-12-05 ZA ZA2011/08920A patent/ZA201108920B/en unknown
-
2012
- 2012-12-20 US US13/722,595 patent/US8946222B2/en not_active Expired - Fee Related
-
2013
- 2013-06-20 PH PH12013501321A patent/PH12013501321B1/en unknown
- 2013-06-20 SM SM201300070T patent/SMT201300070B/xx unknown
-
2014
- 2014-10-02 JP JP2014204220A patent/JP5943053B2/ja not_active Expired - Fee Related
- 2014-12-09 US US14/564,507 patent/US20150322069A1/en not_active Abandoned
-
2015
- 2015-11-25 HR HRP20151273TT patent/HRP20151273T1/hr unknown
-
2016
- 2016-02-04 SM SM201600031T patent/SMT201600031B/it unknown
- 2016-02-10 IL IL244059A patent/IL244059A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ596753A (en) | Phenoxymethyl heterocyclic compounds | |
| HK1217486A1 (zh) | 作爲β-分泌酶抑制剂的全氟化环丙基稠合的1，3-恶嗪-2-胺化合物以及其使用方法 | |
| NZ599597A (en) | IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS | |
| WO2007085556A3 (en) | Use of 4-imidazole derivatives for cns disorders | |
| GEP20146029B (en) | Organic compounds | |
| NZ597511A (en) | Diazahomoadamantane derivatives and methods of use thereof | |
| WO2007149395A3 (en) | 2,5-substituted oxazole derivatives as protein kinase inhibitors for the treatment of cancer | |
| MX2015011313A (es) | Compuestos perfluorados de 5,6-dihidro-4h-1,3-oxazin-2-amina como inhibidores de beta-secretasa y metodos de uso. | |
| NO20091478L (no) | Aminometyl-4-imidazoler | |
| WO2005095357A3 (en) | Pyrimidine derivatives and methods of treatment related to the use thereof | |
| CA2706866A1 (en) | Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10 | |
| NZ595571A (en) | Pyrazole compounds and uses thereof | |
| MX2010008469A (es) | Pirazolopirimidinas, procedimiento para su preparacion y su uso como medicina. | |
| WO2009097287A9 (en) | Compounds and compositions as kinase inhibitors | |
| WO2008155572A3 (en) | Fused quinoline derivatives useful as gaba modulators | |
| BRPI0408910A (pt) | composto, composição farmacêutica e métodos para a profilaxia ou o tratamento de doenças ou condições e para a produção de uma composição farmacêutica | |
| PH12013502263A1 (en) | Substituted benzamide derivatives | |
| MX354815B (es) | Derivados heterociclicos como receptores asociados con las aminas traza (taars). | |
| CR9622A (es) | Derivados de pirazolo[3,4-d]azepina como antagonistas de histamina h3 | |
| IL202236A0 (en) | Prolinamide derivatives as nk3 antagonists | |
| TW200626152A (en) | Pyridine derivatives and pharmaceutical compositions and uses thereof | |
| AU2014368601B2 (en) | Quinazolin-THF-amines as PDE1 inhibitors | |
| MX2016001080A (es) | Derivados de pirroloquinolina como antagonistas de 5-ht6, metodo de preparacion y uso de los mismos. | |
| EP2048139A4 (en) | PROCESS FOR THE PRODUCTION OF (±) -3a, 6,6,9a-TETRAMETHYLDECAHYDRONAPHTO [2,1-b] FURAN-2 (1H) -ONE | |
| MX2012001799A (es) | Derivados de pirrolidina como antagonistas del receptor de neuroquinona 3 (nk3). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 18 DEC 2016 BY COMPUTER PACKAGES INC Effective date: 20140429 |
|
| LAPS | Patent lapsed |